-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)
Analyzing Valneva (NASDAQ:VALN) & Titan Pharmaceuticals (NASDAQ:TTNP)
Valneva (NASDAQ:VALN – Get Rating) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
Earnings & Valuation
This table compares Valneva and Titan Pharmaceuticals' top-line revenue, earnings per share and valuation.
Get Valneva alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.52 | -$86.87 million | N/A | N/A |
Titan Pharmaceuticals | $1.53 million | 9.36 | -$8.78 million | N/A | N/A |
Titan Pharmaceuticals has lower revenue, but higher earnings than Valneva.
Institutional & Insider Ownership
15.8% of Valneva shares are owned by institutional investors. Comparatively, 32.5% of Titan Pharmaceuticals shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 2.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.Profitability
This table compares Valneva and Titan Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Titan Pharmaceuticals | -1,779.72% | -183.12% | -123.74% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Valneva and Titan Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 0 | 2 | 1 | 0 | 2.33 |
Titan Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 66.89%. Given Valneva's stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Titan Pharmaceuticals.
Volatility & Risk
Valneva has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Valneva beats Titan Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Valneva
(Get Rating)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
About Titan Pharmaceuticals
(Get Rating)
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
Valneva (NASDAQ:VALN – Get Rating) and Titan Pharmaceuticals (NASDAQ:TTNP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.
瓦爾內瓦(納斯達克:VALN-GET評級)和泰坦製藥(納斯達克:TTNP-GET評級)都是小盤醫療公司,但哪一家是優勢投資?我們將根據這兩家公司的股息、風險、收益、機構所有權、盈利能力、估值和分析師建議的強弱對它們進行比較。
Earnings & Valuation
收益與估值
This table compares Valneva and Titan Pharmaceuticals' top-line revenue, earnings per share and valuation.
該表格比較了Valneva和Titan PharmPharmticals的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.52 | -$86.87 million | N/A | N/A |
Titan Pharmaceuticals | $1.53 million | 9.36 | -$8.78 million | N/A | N/A |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
瓦爾尼瓦 | 4.1185億美元 | 2.52 | -8,687萬元 | 不適用 | 不適用 |
泰坦製藥 | 153萬美元 | 9.36 | -878萬元 | 不適用 | 不適用 |
Titan Pharmaceuticals has lower revenue, but higher earnings than Valneva.
泰坦製藥的營收低於Valneva,但盈利高於Valneva。
Institutional & Insider Ownership
機構與內部人持股
Profitability
盈利能力
This table compares Valneva and Titan Pharmaceuticals' net margins, return on equity and return on assets.
此表比較了Valneva和Titan製藥公司的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Titan Pharmaceuticals | -1,779.72% | -183.12% | -123.74% |
淨利潤率 | 股本回報率 | 資產回報率 | |
瓦爾尼瓦 | 不適用 | 不適用 | 不適用 |
泰坦製藥 | -1,779.72% | -183.12% | -123.74% |
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for Valneva and Titan Pharmaceuticals, as provided by MarketBeat.
這是MarketBeat提供的Valneva和Titan PharmPharmticals最近的評級和推薦摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 0 | 2 | 1 | 0 | 2.33 |
Titan Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
瓦爾尼瓦 | 0 | 2 | 1 | 0 | 2.33 |
泰坦製藥 | 0 | 1 | 0 | 0 | 2.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 66.89%. Given Valneva's stronger consensus rating and higher probable upside, research analysts clearly believe Valneva is more favorable than Titan Pharmaceuticals.
Valneva目前的共識目標價為25.00美元,表明潛在上行空間為66.89%。鑑於Valneva的更高共識評級和更高的可能上行空間,研究分析師顯然認為Valneva比泰坦製藥更有利。
Volatility & Risk
波動性與風險
Valneva has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Valneva的貝塔係數為2.84,這意味着其股價的波動性比標準普爾500指數高出184%。相比之下,泰坦製藥的貝塔係數為1.02,這意味着其股價的波動性比標準普爾500指數高出2%。
Summary
摘要
Valneva beats Titan Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
在兩隻股票比較的12個因素中,Valneva有9個勝過泰坦製藥。
About Valneva
關於瓦爾尼瓦
(Get Rating)
(獲取評級)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Valneva SE是一家專業疫苗公司,專注於針對未得到滿足需求的傳染病的預防性疫苗的開發和商業化。該公司面向旅行者的商業疫苗包括IXIARO,一種以Vero細胞培養為基礎的滅活日本腦炎疫苗,用於主動免疫日本腦炎;杜考拉,一種口服疫苗,用於預防霍亂弧菌和/或產生產腸毒素大腸桿菌的不耐熱毒素引起的腹瀉;以及VLA2001,一種針對SARS-CoV-2的候選疫苗。該公司還開發了VLA15和VLA1553。VLA15是一種候選疫苗,已經完成了針對疏螺旋體的第二階段臨牀試驗;VLA1553是一種候選疫苗,正在進行鍼對基孔肯雅病毒的第三階段臨牀試驗。它的產品銷往美國、加拿大、德國、奧地利、北歐、英國、其他歐洲國家和國際市場。Valneva SE與輝瑞公司合作共同開發萊姆病疫苗並將其商業化,並與布坦坦研究所合作開發、製造和營銷單針基孔肯雅病疫苗。該公司成立於1998年,總部設在法國聖赫爾布賴恩。
About Titan Pharmaceuticals
關於泰坦製藥公司
(Get Rating)
(獲取評級)
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
泰坦製藥公司利用其長期、持續的藥物輸送平臺ProNeura,致力於開發治療慢性疾病的療法。它的主要產品是普羅布芬,一種用於阿片成癮維持治療的丁丙諾啡植入劑。該公司由Louis R.Bucalo於1992年2月7日創立,總部設在加利福尼亞州舊金山南部。
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
接受Valneva Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Valneva和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧